SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ashton G)
 

Sökning: WFRF:(Ashton G) > (2015-2019) > Aurora kinase inhib...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006546naa a2200661 4500
001oai:DiVA.org:uu-279559
003SwePub
008160302s2016 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2795592 URI
0247 a https://doi.org/10.1126/scitranslmed.aad23552 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Ashton, Susanu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
2451 0a Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo
264 1b American Association for the Advancement of Science (AAAS),c 2016
338 a print2 rdacarrier
520 a Efforts to apply nanotechnology in cancer have focused almost exclusively on the delivery of cytotoxic drugs to improve therapeutic index. There has been little consideration of molecularly targeted agents, in particular kinase inhibitors, which can also present considerable therapeutic index limitations. We describe the development of Accurin polymeric nanoparticles that encapsulate the clinical candidate AZD2811, an Aurora B kinase inhibitor, using an ion pairing approach. Accurins increase biodistribution to tumor sites and provide extended release of encapsulated drug payloads. AZD2811 nanoparticles containing pharmaceutically acceptable organic acids as ion pairing agents displayed continuous drug release for more than 1 week in vitro and a corresponding extended pharmacodynamic reduction of tumor phosphorylated histone H3 levels in vivo for up to 96 hours after a single administration. A specific AZD2811 nanoparticle formulation profile showed accumulation and retention in tumors with minimal impact on bone marrow pathology, and resulted in lower toxicity and increased efficacy in multiple tumor models at half the dose intensity of AZD1152, a water-soluble prodrug of AZD2811. These studies demonstrate that AZD2811 can be formulated in nanoparticles using ion pairing agents to give improved efficacy and tolerability in preclinical models with less frequent dosing. Accurins specifically, and nanotechnology in general, can increase the therapeutic index of molecularly targeted agents, including kinase inhibitors targeting cell cycle and oncogenic signal transduction pathways, which have to date proved toxic in humans.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Cell- och molekylärbiologi0 (SwePub)301082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Cell and Molecular Biology0 (SwePub)301082 hsv//eng
7001 a Song, Young Hou BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Nolan, Jimu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Cadogan, Elaineu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Murray, Jimu AstraZeneca, Pharmaceut Dev, Macclesfield SK10 2NX, Cheshire, England.4 aut
7001 a Odedra, Rajeshu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Foster, Johnu AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Hall, Peter A.u AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Low, Susanu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Taylor, Paulau AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Ellston, Rebeccau AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Polanska, Urszula M.u AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Wilson, Joanneu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Howes, Colinu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Smith, Aaronu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Goodwin, Richard J. A.u AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Swales, John G.u AstraZeneca R&D, Drug Safety & Metab, Innovat Med, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Strittmatter, Nicoleu Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London SW7 2AZ, England.4 aut
7001 a Takats, Zoltanu Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London SW7 2AZ, England.4 aut
7001 a Nilsson, Annau Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)annil134
7001 a Andrén, Peru Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)perandre
7001 a Trueman, Dawnu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Walker, Mikeu AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Reimer, Corinne L.u AstraZeneca, Oncol iMED, Gatehouse Pk, Boston, MA 02451 USA.4 aut
7001 a Troiano, Gregu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Parsons, Donaldu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a De Witt, Davidu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Ashford, Marianneu AstraZeneca, Pharmaceut Dev, Macclesfield SK10 2NX, Cheshire, England.4 aut
7001 a Hrkach, Jeffu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Zale, Stephenu BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 aut
7001 a Jewsbury, Philip J.u AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7001 a Barry, Simon T.u AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.4 aut
7102 a AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England.b BIND Therapeut, 325 Vassar St, Cambridge, MA 02139 USA.4 org
7730 t Science Translational Medicined : American Association for the Advancement of Science (AAAS)g 8:325q 8:325x 1946-6234x 1946-6242
8564 u http://hdl.handle.net/10044/1/37595
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-279559
8564 8u https://doi.org/10.1126/scitranslmed.aad2355

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy